NCT00043368已完成2 期
A Continuation Study Of PF-3512676 (CPG 7909) Injection In Patients With Metastatic Or Recurrent Malignancies Who Have Stable Disease Or Who Have Responded To Pf-3512676 Injection Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 31
- 试验地点
- 1
- 主要终点
- Adverse Events and DLTs will be evaluated by the Investigator and summarized.
研究概览
简要总结
This protocol allows patients who completed Coley oncology studies using PF-3512676 (CPG 7909) Injection to continue receiving the treatment until disease progression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Immediate (within 4 weeks) prior completion of a clinical trial of PF-3512676 Injection alone or in combination with other anti-neoplastic treatment for malignancy.
排除标准
- •The patient has received any anti-neoplastic therapy since completing a prior trial with PF-3512676 Injection, or has participated in another clinical trial following participation in a trial with PF-3512676 Injection.
研究组 & 干预措施
1
Experimental
Patients will be treated with the same dosing regimen and schedule of PF-3512676 Injection with which they were treated at the end of the previous PF-3512676 Injection trial. Any proposed changes to their schedule/regimen will be at the discretion of the treating physician, following consultation with Coley.
干预措施: PF-3512676 (Drug)
结局指标
主要结局
Adverse Events and DLTs will be evaluated by the Investigator and summarized.
时间窗: indeterminate
次要结局
- No formal statistical analysis of this study will be conducted. All clinical data may be summarized and included in data listings.(indeterminate)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
CPG 7909 in Patients Wih Stage IV Renal Cell CancerCarcinoma, Renal CellNCT00043407Pfizer42
已完成
2 期
CCI-779 in Treating Patients With Recurrent Glioblastoma MultiformeAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain TumorNCT00016328National Cancer Institute (NCI)33
已完成
2 期
E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue SarcomaSoft Tissue SarcomaNCT00413192Eisai Inc.128
已完成
3 期
Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid ArthritisRheumatoid ArthritisNCT00548834UCB Pharma220
已完成
2 期
Temsirolimus in Treating Patients With Metastatic Neuroendocrine CarcinomaMetastatic Gastrointestinal Carcinoid TumorPulmonary Carcinoid TumorRecurrent Gastrointestinal Carcinoid TumorRecurrent Islet Cell CarcinomaNCT00093782National Cancer Institute (NCI)36